Traws Pharma, Inc.

TRAW

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Gemcitabine	Phase 3	Metastatic Pancreatic Adenocarcinoma	-
rigosertib sodium	Phase 3	Myelodysplastic Syndromes	-
Azacitidine	Phase 2	Myelodysplastic Syndrome	-
Oral rigosertib	Phase 2	Myelodysplastic Syndromes	-
Narazaciclib	Phase 2	Endometrioid Endometrial Cancer	-
ON 01910.Na	Phase 2	Myelodysplastic Syndrome	-
rigosertib	Phase 2	Head and Neck Squamous Cell Carcinoma	-
Ratutrelvir (83-0060) non-randomised	Phase 2	COVID - 19	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

December 2025~Ratutrelvir (83-0060) non-randomised

Primary completion for Ratutrelvir (83-0060) non-randomised trial (NCT07157007) in COVID - 19

Phase 2

January 2026~Narazaciclib

Primary completion for Narazaciclib trial (NCT05705505) in Endometrioid Endometrial Cancer

Regulatory Approvals

TRAW News